KOSDAQBiotech & Pharma384470

Coreline Soft

₩2,040▼ 1.45%2026-11-18 close
Market Cap
₩36.6B
Turnover
₩10,335,255
Volume
5.1K
Shares out.
18M
PER
—
PBR
3.7×
EPS
-₩667
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Overseas Growth and Recurring Revenue Narrow Losses

Coreline Soft's third-quarter 2026 revenue of KRW 2.33 billion was the highest quarterly figure in the disclosed series, but operating losses and negative operating cash flow persist, so a return to profit has not yet been confirmed.

  1. 1

    Cumulative consolidated revenue for January to September 2026 reached KRW 5.22 billion, up 76.4% year on year, and overseas sales accounted for 53.7% of the total.

  2. 2

    Software recurring revenue rose 79.0% year on year to KRW 2.32 billion in the first nine months of 2026, lifting its share of software sales to 55.0%.

  3. 3

    Operating loss narrowed from KRW 3.59 billion in Q3 2025 to KRW 2.22 billion in Q3 2026, yet losses have continued for five consecutive quarters.

  4. 4

    The operating cash outflow widened every year from negative KRW 8.78 billion in 2022 to negative KRW 11.6 billion in 2025, and total liabilities of KRW 22.6 billion exceed total equity of KRW 18.2 billion at year-end 2025.

  5. 5

    The next regular filing is the 2026 annual report, which will show fourth-quarter 2026 results and full-year operating cash flow as the next checkpoints.

02

Business structure

Coreline Soft is a medical AI software company that analyzes chest CT images, and its flagship product is the lung cancer screening solution in the AVIEW LCS family.

The company promotes a One CT, Multi-Disease strategy that analyzes lung nodules, emphysema and COPD, coronary artery calcification (CAC), and interstitial lung abnormalities from a single chest CT scan.

It has taken part in Korea's national lung cancer screening since 2019, and the company says it has secured lung cancer screening contracts for nine consecutive years.

Cumulative revenue for January to September 2026 of KRW 5.22 billion split into KRW 2.4 billion domestic and KRW 2.8 billion overseas, and the overseas share rose from 38% in 2024 and 40% in 2025 to 53.7%. Germany is the center of overseas business.

Low-dose CT lung cancer screening for high-risk groups has been carried out within the statutory health insurance system there since April 2026. As of November 2026, the company said it had contracted with 142 of roughly 310 expected participating facilities and that 50 of them were operating the software.

Revenue comes from implementation sales recognized at installation and recurring sales from subscription and pay-per-use models. In January to September 2026, implementation sales were about KRW 850 million and software recurring revenue was KRW 2.32 billion.

Distribution extends beyond direct hospital sales to B2B deals with global medical device companies, AI platforms, and national or multi-institution projects.

In Japan, the company received PMDA approval in September 2026 and in October 2026 signed a supply and linkage agreement for AVIEW CAC with teleradiology company Doctor Net.

In Korea, it was selected as a solution supplier for 9 of 17 regional responsibility hospitals in a Ministry of Health and Welfare AI-based clinical system support program.

In competition, lung nodule detection overlaps with players such as Infervision, while in risk assessment the company works with US-based Optellum to connect functions. The company says it holds 12 FDA 510(k) clearances and more than 20 US patents.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1B-₩3.6B−368.4%
2025Q4₩1.3B-₩2.9B−220.5%
2026Q1₩1.3B-₩3.1B−238.8%
2026Q2₩1.6B-₩2.4B−149.4%
2026Q3₩2.3B-₩2.2B−95.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩4.1B-₩10.2B-₩10.2B−248.4%−469.6%157.5%
2023₩4.1B-₩11.7B-₩14.1B−284.3%−120.3%35.5%
2024₩3.9B-₩13.8B-₩14.1B−350.7%−385.9%573.2%
2025₩4.3B-₩13.4B-₩14.5B−313.9%−79.8%124.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue under the disclosed figures was KRW 4.09 billion in 2022, KRW 4.1 billion in 2023 (up 0.2% year on year), KRW 3.93 billion in 2024 (down 4.2%), and KRW 4.28 billion in 2025 (up 9.0%). Among 2022 to 2025, 2025 was the largest year and 2024 was the smallest.

Operating loss widened from KRW 10.2 billion in 2022 to KRW 11.7 billion in 2023 and KRW 13.8 billion in 2024, then narrowed to KRW 13.4 billion in 2025. The operating margin improved from -248.4% in 2022, -284.3% in 2023 and -350.7% in 2024 to -313.9% in 2025.

Net loss attributable to controlling shareholders was KRW 10.2 billion in 2022, KRW 14.1 billion in 2023, KRW 14.1 billion in 2024 and KRW 14.5 billion in 2025, and the company recorded a loss in each of those four years from 2022 to 2025.

Net loss including non-controlling interests was KRW 10.2 billion, KRW 14.1 billion, KRW 14.1 billion and KRW 14.5 billion over the same years.

Operating cash flow was negative KRW 8.78 billion in 2022, negative KRW 10.3 billion in 2023, negative KRW 10.8 billion in 2024 and negative KRW 11.6 billion in 2025, so the outflow grew each year.

The debt-to-equity ratio was 157.5% in 2022, 35.5% in 2023, 573.2% in 2024 and 124.5% in 2025, with large swings across years. At year-end 2025, total equity was KRW 18.2 billion, all of it attributable to controlling shareholders, and total liabilities were KRW 22.6 billion.

Quarterly revenue was KRW 975 million in Q3 2025, KRW 1.33 billion in Q4 2025 (up 36.2% from the prior quarter), KRW 1.3 billion in Q1 2026 (down 2.1%), KRW 1.59 billion in Q2 2026 (up 22.0%) and KRW 2.33 billion in Q3 2026 (up 46.9%).

Operating loss was KRW 3.59 billion in Q3 2025, KRW 2.93 billion in Q4 2025, KRW 3.1 billion in Q1 2026, KRW 2.37 billion in Q2 2026 and KRW 2.22 billion in Q3 2026, which is five consecutive quarters of losses since Q3 2025.

Net loss attributable to controlling shareholders was KRW 3.7 billion, KRW 3.25 billion, KRW 3.22 billion, KRW 3.72 billion and KRW 2.44 billion across the same five quarters, and the four quarters from Q4 2025 to Q3 2026 total KRW 12.6 billion.

The company said cumulative operating loss for January to September 2026 of KRW 7.69 billion was down 26.9% year on year, and that about 80% of the roughly KRW 2.82 billion improvement came from higher revenue rather than cost cuts.

Cumulative revenue for the first nine months still includes about KRW 850 million of implementation sales, which differ in nature from recurring revenue.

05

Industry analysis

Lung cancer screening with low-dose CT is expanding as a national program. The company argues that even after clinical evidence is established, lung cancer screening takes a long time to settle into national health systems, and that the global rollout is only now beginning.

In Germany, screening within the statutory health insurance system began in April 2026, and participating medical institutions have started preparing in earnest.

Screening requires first and second reads, follow-up, comparison with prior images and quality control, which raises the importance of workflow tools that link hospitals and support continuous operation over stand-alone reading software.

The center of gravity in medical imaging AI is also shifting from individual algorithm performance toward connection with existing PACS and RIS systems and modular workflows.

In the United States, a new HCPCS code, G0680, was created in 2026 for billing of coronary artery calcification analysis, so added risk analysis from chest CT has begun to enter a separate billing framework.

On the competitive side, Infervision and others operate in lung nodule detection, while Optellum is active in risk assessment. Coreline Soft has focused on the detection stage and, through its work with Optellum, chosen to connect risk assessment and follow-up management as well.

The company cites its experience applying AI in real clinical workflows in two different settings, Korea's national lung cancer screening and Germany's statutory health insurance-based screening, as a strength.

06

Outlook

The following facts are confirmable from company statements.

About half of the German contracts secured in the first half of 2026 have been reflected in revenue, and the company said the rest will be recognized sequentially from the second half of 2026 onward, depending on system build-out, integration, and the start of screening and usage.

In May 2026 the company was selected for a 2026 first-round multi-ministry advanced medical device R&D program, receiving support of KRW 2.2 billion over three years.

The project targets an automated lung nodule detection solution for cardiac CT, called AVIEW IPN, with the aim of obtaining FDA 510(k) clearance through an overseas clinical study.

The company also presented an AI-based lung disease analysis workflow platform at the World Conference on Lung Cancer (WCLC 2026) in September 2026. In the United States, it renewed a subscription contract with 3DR Labs for a fourth year in June 2026 and said AVIEW annual usage at that customer rose 60%.

In August 2026 it said it was pursuing supply of its AVIEW Lung Nodule CAD software through Optellum's LungOS platform. In Japan, the key checkpoint is whether the Doctor Net AVIEW CAC agreement translates into more analyzed cases and more participating institutions.

The company also said it will expand into imaging biomarkers and quantitative analysis for drug trials. However, the timing of US clearance and the pace of German contract go-live have not been disclosed in specific terms, so they remain plans until they appear in reported results.

07

Valuation

PER
—
PBR
3.7×
ROE
-79.2%
EPS
-₩667
BPS
₩571
Dividend per share
₩0

Price-to-book is well above 1x, and market capitalization also exceeds total equity. Because the four quarters from Q4 2025 to Q3 2026 all show losses attributable to controlling shareholders, the earnings-based multiple PER cannot be calculated.

The company pays no meaningful dividend given its losses, so valuation comparisons based on dividends do not hold. No swing to profit has been confirmed from 2022 through 2025, and what is visible instead is a narrowing operating loss alongside rising revenue.

Factors cited on the positive side are overseas revenue growth and a higher share of recurring revenue. Factors on the negative side are the cumulative losses and liabilities that exceed equity.

The debt-to-equity ratio was 124.5% at year-end 2025, and operating cash outflows have widened for four consecutive years, so whether the company raises external funding is a checkpoint for its financial capacity.

Market capitalization and price multiples move daily with the share price, so the level comparisons here should be read together with the direction of earnings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Overseas-led growth

Cumulative overseas revenue for January to September 2026 was KRW 2.8 billion, up 152.3% year on year and 53.7% of total revenue. Of the KRW 2.26 billion total revenue increase, KRW 1.69 billion came from overseas. The company said new German customer contracts rose from 10 in 2025 to a cumulative 77 by July 2026.

Rising recurring revenue share

Software recurring revenue rose 79.0% year on year to KRW 2.32 billion in the first nine months of 2026, and its share of software sales rose from 45.0% to 55.0%. Subscription and pay-per-use revenue builds as medical institutions operate the software and examination volumes accumulate. The company said standalone recurring revenue in Q3 2026 was KRW 950 million, up 99% year on year.

Revenue-driven loss narrowing

Q3 2026 operating loss of KRW 2.22 billion narrowed from KRW 3.59 billion in Q3 2025, and the company said this was its lowest quarterly level since listing. According to the company, about 80% of the profit improvement came from higher revenue rather than cost reduction. Management said it expects operating leverage to grow as business scale expands.

09

Bear factors

Cumulative losses and cash outflows

Net loss attributable to controlling shareholders has run for four consecutive years from 2022 to 2025, and the 2025 figure of KRW 14.5 billion was the largest in that period. Operating cash outflow widened from negative KRW 8.78 billion in 2022 to negative KRW 11.6 billion in 2025.

Despite improving earnings trends, bears point out that the company is still some distance from generating cash.

Contract-to-revenue lag

The company said only about half of the contracts it secured in the first half of 2026 have been reflected in revenue. The remainder depends on system build-out, integration, and the timing of screening start and usage.

Usage-based contracts grow revenue only as examination volumes increase, so a rise in contract count does not translate directly into revenue.

Overseas concentration and quarterly volatility

Quarterly revenue fell 2.1% to KRW 1.3 billion in Q1 2026 from the prior quarter, and the quarterly series does not yet show a long run of steady growth. With the overseas share at 53.7%, results are more exposed to screening policy and contract go-live pace in specific countries such as Germany. Policy changes in individual countries could increase earnings volatility.

10

Risk factors

Policy and reimbursement

German lung cancer screening runs within the statutory health insurance system, so changes to coverage or screening criteria could affect contract go-live and usage.

In Korea, AI-based lung nodule detection and lung cancer prediction technology has been designated as an evaluation-pending new medical technology, so the timing of formal reimbursement inclusion is not set. Regulatory differences across countries are a key variable for the pace of overseas expansion.

Shifting platform competition

Medical imaging AI competition is moving from algorithm performance toward integration with existing PACS and RIS systems and modular workflow offerings. If partnerships with platform companies lag, detection-stage technology could be displaced in hospital purchasing choices.

The division of roles between lung nodule AI vendors such as Infervision and risk-assessment vendors such as Optellum is also a variable.

Financial capacity

Total liabilities of KRW 22.6 billion at year-end 2025 exceed total equity of KRW 18.2 billion, and operating cash outflows continue. Net loss attributable to controlling shareholders for the four quarters from Q4 2025 to Q3 2026 totals KRW 12.6 billion.

If the narrowing of losses does not continue or funding conditions change, the pace of overseas build-out and clinical investment could be affected.

11

What to watch next

  1. December 31, 2026 (end of fiscal 2026)

    This marks the point at which to gauge how much of the German contract backlog not yet in revenue has gone live by year-end and how quickly it converts into usage-based revenue.

  2. March 31, 2027 (filing deadline for the 2026 annual report)

    This is the next regular filing, which will disclose fourth-quarter 2026 results, full-year operating cash flow and the debt structure. The checkpoint is how fourth-quarter operating loss compares with KRW 2.22 billion in Q3 2026.

  3. May 15, 2027 (filing deadline for the Q1 2027 quarterly report)

    This is the point to check whether operating loss and net loss attributable to controlling shareholders keep narrowing and whether the recurring revenue and overseas shares hold near 53.7%.

  4. 2027 onward (timing not disclosed)

    Results of the US overseas clinical study, progress toward FDA 510(k) clearance, and growth in AVIEW CAC analysis volume through the Doctor Net link will serve as the next evidence of business expansion.

12

Overall view

Coreline Soft recorded KRW 2.33 billion in Q3 2026 revenue, the highest quarterly figure in the disclosed series, and overseas sales and recurring revenue grew together, which shows the business mix shifting.

Operating loss narrowed from KRW 3.59 billion in Q3 2025 to KRW 2.22 billion in Q3 2026, and the company said most of the improvement came from higher revenue.

However, net loss attributable to controlling shareholders has continued for four consecutive years from 2022 to 2025, and total liabilities exceed total equity at year-end 2025.

The operating cash outflow has also widened every year since 2022, so it has not yet been confirmed that the earnings improvement is turning into cash generation. Only about half of the German contracts have been reflected in revenue, so contract go-live and rising usage are the key variables for upcoming results.

On valuation, an earnings-based multiple cannot be calculated and price-to-book is well above 1x, so how the market reflects business improvement is the central interpretive question.

Strengths are overseas growth and the recurring revenue structure, while weaknesses are cumulative losses, cash outflows, and the lag between contracts and revenue. The next checkpoint is the full-year operating margin and operating cash flow in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. wowtv.co.kr
  2. etoday.co.kr
  3. datanet.co.kr
  4. pinpointnews.co.kr
  5. dailypharm.com
  6. monews.co.kr
  7. wowtv.co.kr
  8. news.nate.com
  9. news.nate.com
  10. news.nate.com
  11. bosa.co.kr
  12. rapportian.com
  13. bosa.co.kr
  14. corelinesoft.com
  15. rapportian.com
  16. biotimes.co.kr
  17. newsis.com
  18. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis